Sublingual Apomorphine in Refractory Restless Legs Syndrome

Summary

This is an open label, short placebo-controlled trial in Restless Legs Syndrome (RLS) patients inadequately treated with standard therapy. Investigators hypothesize that the study drug, sublingual apomorphine (Kynmobi), may improve RLS breakthrough symptoms. This study is designed to determine if sublingual apomorphine improves breakthrough symptoms in RLS patients, in addition to subjective responses.

Timeline

Start

2022-09-01

Primary completion

2023-03-01

Completion

2023-03-01

Drugs

Indications